Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 5Recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Heart Failure 2Neoplasms, Second Primary 1Cardiotoxicity 1Breast Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 562Specimen Handling 490Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 406Radiotherapy 353Gemcitabine 314Bevacizumab 313Paclitaxel 298Biopsy 290Drug Therapy 283Blood Specimen Collection 248Capecitabine 245Oxaliplatin 241fludarabine 240Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 205Dexamethasone 187Radiosurgery 182Rituximab 159Standard of Care 158Pemetrexed 156Surgical Procedures, Operative 148durvalumab 145atezolizumab 145Leucovorin 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × sacubitril and valsartan sodium hydrate drug combination × Clear all
NCT05194111 2026-03-13

TREAT-HF

Virginia Commonwealth University

Phase 1/2 Recruiting
53 enrolled

Heart Failure

NCT05465031 2025-03-14

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Silesian Centre for Heart Diseases

Phase 4 Recruiting
600 enrolled
Breast

Breast Diseases, Breast Neoplasms, Heart Failure, Neoplasms, Second Primary, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡